Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice

Blood

Volumn 118, Issue 4, 2011, Pages 1109-1112

  Meiler, Steffen E ^a   Wade, Marlene ^a   Kutlar, Ferdane ^a   Yerigenahally, Shobha D ^a   Xue, Yongjun ^b   Moutouh de Parseval, Laure A ^c   Corral, Laura G ^b   Swerdlow, Paul S ^d   Kutlar, Abdullah ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b CELGENE CORPORATION   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA; POMALIDOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW SUPPRESSION; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROPOIESIS; EX VIVO STUDY; FLOW CYTOMETRY; HEMOGLOBIN SYNTHESIS; LEUKOCYTE COUNT; LOW DRUG DOSE; MEAN CORPUSCULAR HEMOGLOBIN; MEGAKARYOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SICKLE CELL ANEMIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79960974473     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-319137     Document Type: Article

References (18)

1. Nagel RL, Bookchin RM, Johnson J, et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci U S A. 1979;76(2):670-672. (Pubitemid 9135654)
2. Nagel RL, Erlingsson S, Fabry ME, et al. The Senegal DNA haplotype is associated with the amelioration of anemia in African-American sickle cell anemia patients. Blood. 1991;77(6):1371-1375.
3. Pace BS, Zein S. Understanding mechanisms of gamma-globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction. Dev Dyn. 2006;235(7):1727-1737. (Pubitemid 43902333)
4. Perrine SP. Fetal globin stimulant therapies in the beta- hemoglobinopathies: principles and current potential. Pediatr Ann. 2008;37(5):339-346. (Pubitemid 351847506)
5. Stamatoyannopoulos G, Wood WG, Papayannopoulou T, Nute PE. A new form of hereditary persistence of fetal hemoglobin in blacks and its association with sickle cell trait. Blood. 1975;46(5):683-692.
6. Steinberg MH, Rodgers GP. Pharmacologic modulation of fetal hemoglobin. Medicine (Baltimore). 2001;80(5):328-344. (Pubitemid 32879295)
7. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia: Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317-1322.
8. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645-1651. (Pubitemid 37430269)
9. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4(4):314-322. (Pubitemid 38525287)
10. Crane E, List A. Immunomodulatory drugs. Cancer Invest. 2005;23(7):625-634. (Pubitemid 43286664)
11. Wiernik PH. Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs). Curr Treat Options Oncol. 2009;10(1):1-15.
12. Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol;85(2):129-130.
13. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111(1):86-93.
14. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108(4):1158-1164. (Pubitemid 44232010)
15. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27(27):4563-4569.
16. Moutouh-de Parseval LA, Verhelle D, Glezer E, et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest. 2008;118(1):248-258.
17. Ryan TM, Ciavatta DJ, Townes TM. Knockout-transgenic mouse model of sickle cell disease. Science. 1997;278(5339):873-876. (Pubitemid 27467926)
18. Maier-Redelsperger M, de Montalembert M, Flahault A, et al. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients: the French Study Group on Sickle Cell Disease. Blood. 1998;91(12):4472-4479. (Pubitemid 28270293)